Cybin (HELP) FDA Approvals $8.06 +0.24 (+3.07%) Closing price 04:00 PM EasternExtended Trading$8.12 +0.06 (+0.74%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cybin's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Cybin (HELP). Over the past two years, Cybin has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as HLP003. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. HLP003 FDA Regulatory Events HLP003 is a drug developed by Cybin for the following indication: adjunctive treatment of major depressive disorder ("MDD"). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Update - July 21,2026Enrollment Update Phase 3Drug: HLP003Announced Date: July 21, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder ("MDD").AI SummaryHelus Pharma said it has finished enrolling patients in APPROACH, the first pivotal Phase 3 study in its PARADIGM program for HLP003 in adults with major depressive disorder. The study includes people with moderate to severe MDD who still have symptoms despite taking a stable antidepressant. Reaching full enrollment is an important step toward the company’s planned topline data readout in the fourth quarter of 2026. The broader PARADIGM program is also moving forward. Enrollment is still ongoing in EMBRACE, the second pivotal Phase 3 study. Some participants from APPROACH and EMBRACE may later move into EXTEND, a long-term study designed to gather more safety, durability, and possible redosing data. Helus Pharma said the program is built to support clear and reliable results, with placebo control, safety monitoring, and longer-term follow-up.Read AnnouncementEnrollment Update - June 24,2026Enrollment Update Phase 3Drug: HLP003Announced Date: June 24, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma™ nnounced that enrollment in the APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment.AI SummaryHelus Pharma said enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder is moving ahead as planned and is now more than 86% complete. The company said this study is testing both the safety and effectiveness of HLP003 as an add-on treatment for patients with MDD, and it is part of a larger Phase 3 program. Helus also pointed to earlier Phase 2 results that showed strong and lasting benefits. In those data, patients had about a 23-point drop in MADRS scores after 12 months, following two 16 mg doses given three weeks apart. Response and remission rates were 75% at week 18, then improved to 100% and 71% by 12 months. The company said it remains on track to report topline Phase 3 data in Q4 2026.Read Announcement Cybin FDA Events - Frequently Asked Questions Has Cybin received FDA approval? As of now, Cybin (HELP) has not received any FDA approvals for its therapy in the last two years. What drugs has Cybin submitted to the FDA? In the past two years, Cybin (HELP) has reported FDA regulatory activity for HLP003. What is the most recent FDA event for Cybin? The most recent FDA-related event for Cybin occurred on July 21, 2026, involving HLP003. The update was categorized as "Enrollment Update," with the company reporting: "Helus Pharma announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder ("MDD")." What conditions do Cybin's current drugs treat? Currently, Cybin has one therapy (HLP003) targeting the following condition: adjunctive treatment of major depressive disorder ("MDD"). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Acurx Pharmaceuticals FDA EventsAkebia Therapeutics FDA EventsAltimmune FDA EventsEstrella Immunopharma FDA EventsNiagen Bioscience FDA EventsOmeros FDA EventsOSR FDA EventsRocket Pharmaceuticals FDA EventsTonix Pharmaceuticals FDA EventsZai Lab FDA EventsEli Lilly and Company FDA EventsClearPoint Neuro FDA EventsMoleculin Biotech FDA EventsAprea Therapeutics FDA EventsCapricor Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies SELLAS Life Sciences Group FDA Events Zai Lab FDA Events Harmony Biosciences FDA Events Sionna Therapeutics FDA Events Nanobiotix FDA Events Urogen Pharma FDA Events Rapport Therapeutics FDA Events Aurinia Pharmaceuticals FDA Events HUTCHMED FDA Events Precigen FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:HELP last updated on 7/21/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Update - July 21,2026Enrollment Update Phase 3Drug: HLP003Announced Date: July 21, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder ("MDD").AI SummaryHelus Pharma said it has finished enrolling patients in APPROACH, the first pivotal Phase 3 study in its PARADIGM program for HLP003 in adults with major depressive disorder. The study includes people with moderate to severe MDD who still have symptoms despite taking a stable antidepressant. Reaching full enrollment is an important step toward the company’s planned topline data readout in the fourth quarter of 2026. The broader PARADIGM program is also moving forward. Enrollment is still ongoing in EMBRACE, the second pivotal Phase 3 study. Some participants from APPROACH and EMBRACE may later move into EXTEND, a long-term study designed to gather more safety, durability, and possible redosing data. Helus Pharma said the program is built to support clear and reliable results, with placebo control, safety monitoring, and longer-term follow-up.Read Announcement
Enrollment Update - June 24,2026Enrollment Update Phase 3Drug: HLP003Announced Date: June 24, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma™ nnounced that enrollment in the APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment.AI SummaryHelus Pharma said enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder is moving ahead as planned and is now more than 86% complete. The company said this study is testing both the safety and effectiveness of HLP003 as an add-on treatment for patients with MDD, and it is part of a larger Phase 3 program. Helus also pointed to earlier Phase 2 results that showed strong and lasting benefits. In those data, patients had about a 23-point drop in MADRS scores after 12 months, following two 16 mg doses given three weeks apart. Response and remission rates were 75% at week 18, then improved to 100% and 71% by 12 months. The company said it remains on track to report topline Phase 3 data in Q4 2026.Read Announcement
